Table 1.
Basic characteristics and body adipose tissues per TNM stagea and Fuhrman grade.
| Variable | Total (N = 1039) |
Stage I (N = 454, 43.7%) |
Stage II (N = 91, 8.8%) |
Stage III (N = 174, 16.7%) |
Stage IV (N = 282, 27.1%) |
Unknown stage (N = 38, 3.7%) |
|---|---|---|---|---|---|---|
| Age at diagnosis (years), mean (SD) | 64.8 (11.8) | 63.5 (12.0) | 62.9 (12.6) | 66.0 (10.4) | 65.1 (11.5) | 76.4 (10.4) |
| Sex | ||||||
| Male, n (%) | 643 (61.9%) | 267 (58.8%) | 54 (59.3%) | 118 (67.8%) | 181 (64.2%) | 23 (60.5%) |
| Female, n (%) | 396 (38.1%) | 187 (41.2%) | 37 (40.7%) | 56 (32.2%) | 101 (35.8%) | 15 (39.5%) |
| Morphology | ||||||
| Confirmed ccRCC, n (%) | 655 (63.0%) | 295 (65.0%) | 57 (62.6%) | 134 (77.0%) | 167 (59.2%) | 2 (5.3%) |
| Non-ccRCC or not specified, n (%) | 384 (37.0%) | 159 (35.0%) | 34 (37.4%) | 40 (23.0%) | 115 (40.8%) | 36 (94.7%) |
| BMI | ||||||
| Mean (SD) | 26.6 (4.35) | 27.1 (4.72) | 27.0 (4.67) | 26.2 (3.58) | 25.8 (3.94) | 26.7 (3.95) |
| Missing, n (%) | 160 (15.4) | 55 (12.1%) | 7 (7.7%) | 11 (6.3%) | 76 (27.0%) | 11 (28.9%) |
| VAT (cm2), median (IQR) | 145 (73, 220) | 168 (93, 239) | 147 (59, 224) | 149 (77, 214) | 110 (53, 181) | 135 (77, 244) |
| SAT (cm2), median (IQR) | 156 (107, 218) | 166 (123, 230) | 167 (107, 213) | 145 (105, 216) | 137 (98, 189) | 139 (97, 188) |
| TAT (cm2), median (IQR) | 315 (216, 427) | 346 (255, 452) | 301 (211, 429) | 326 (211, 399) | 258 (176, 375) | 302 (198, 441) |
| rVAT (%), median (IQR) | 45.8 (30.7, 58.7) | 46.4 (31.9, 60.1) | 43.7 (30.1, 57.9) | 48.7 (32.7, 60.7) | 42.4 (28.5, 53.2) | 53.2 (34.5, 62.3) |
| Variable | Total (N = 1039) |
Grade 1 (N = 76, 7.3%) |
Grade 2 (N = 334, 32.1%) |
Grade (3 + 4) (N = 320, 30.8%) |
Unknown grade (N = 309, 29.8%) |
|
|---|---|---|---|---|---|---|
| Age at diagnosis, year mean (SD) | 64.8 (11.8) | 62.8 (11.6) | 62.9 (11.7) | 63.4 (11.2) | 68.9 (11.8) | |
| Sex | ||||||
| Male, n (%) | 643 (61.9%) | 34 (44.7%) | 207 (62.0%) | 220 (68.8%) | 182 (58.9%) | |
| Female, n (%) | 396 (38.1%) | 42 (55.3%) | 121 (38.0%) | 100 (31.3%) | 127 (41.1%) | |
| Morphology | ||||||
| Confirmed ccRCC, n (%) | 655 (63.0%) | 57 (75.0%) | 260 (77.8%) | 236 (73.8%) | 207 (67.0%) | |
| Non-ccRCC or not specified, n (%) | 384 (37.0%) | 19 (25.0%) | 74 (22.2%) | 84 (26.3%) | 102 (33.0%) | |
| BMI | ||||||
| Mean (SD) | 26.6 (4.35) | 27.9 (5.24) | 26.9 (4.26) | 26.2 (4.50) | 26.3 (3.90) | |
| Missing, n (%) | 160 (15.4) | 9 (11.8%) | 41 (12.3%) | 39 (12.2%) | 71 (23.0%) | |
| VAT (cm2), median (IQR) | 145 (73, 220) | 169 (111, 235) | 159 (91, 237) | 143 (62, 205) | 125 (61, 204) | |
| SAT (cm2), median (IQR) | 156 (107, 218) | 199 (138, 241) | 167 (120, 227) | 140 (102, 191) | 148 (99, 215) | |
| TAT (cm2), median (IQR) | 315 (216, 427) | 348 (290, 492) | 345 (242, 447) | 293 (186, 397) | 288 (196, 401) | |
| rVAT (%), median (IQR) | 45.8 (30.7, 58.7) | 43.0 (31.3, 57.1) | 46.4 (32.1, 59.5) | 46.5 (31.2, 58.2) | 44.6 (29.3, 59.7) | |
ccRCC, clear cell renal cell carcinoma; BMI, body mass index; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; TAT, total adipose tissue; rVAT, relative visceral adipose tissue.
aTumor staging based on pathological completed with clinical TNM classification used in the year of incidence (6th edition up to and including 2009, 7th edition from 2010–2012).